PT1460066E - Compostos de piperazina úteis como inibidores de taquicininas - Google Patents

Compostos de piperazina úteis como inibidores de taquicininas Download PDF

Info

Publication number: PT1460066E
Authority: PT; Portugal
Prior art keywords: tachykinins; inhibitors; piperazine compounds; piperazine; compounds
Prior art date: 1999-10-07

Application number

PT04076632T

Other languages

English (en)

Inventor

Giuseppe Alvaro

Riccardo Giovannini

Romano Di Fabio

Giuseppe Guercio

Yves St-Denis

Antonella Ursini

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-10-07

Filing date

2000-10-05

Publication date

2009-09-10

2000-10-05 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2009-09-10 Publication of PT1460066E publication Critical patent/PT1460066E/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Addiction (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Hydrogenated Pyridines (AREA)

PT04076632T 1999-10-07 2000-10-05 Compostos de piperazina úteis como inibidores de taquicininas PT1460066E (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB9923748.9A GB9923748D0 (en)	1999-10-07	1999-10-07	Chemical compounds

Publications (1)

Publication Number	Publication Date
PT1460066E true PT1460066E (pt)	2009-09-10

Family

ID=10862304

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
PT04076650T PT1454901E (pt)	1999-10-07	2000-10-05	Composições farmacêuticas compreendendo antagonistas de taquicininas e um inibidor de recaptação de serotonina
PT00969414T PT1218359E (pt)	1999-10-07	2000-10-05	Compostos de piperazina uteis como antagonistas de taquiquininas
PT04076632T PT1460066E (pt)	1999-10-07	2000-10-05	Compostos de piperazina úteis como inibidores de taquicininas

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
PT04076650T PT1454901E (pt)	1999-10-07	2000-10-05	Composições farmacêuticas compreendendo antagonistas de taquicininas e um inibidor de recaptação de serotonina
PT00969414T PT1218359E (pt)	1999-10-07	2000-10-05	Compostos de piperazina uteis como antagonistas de taquiquininas

Country Status (33)

Country	Link
US (6)	US6951861B1 (pt)
EP (3)	EP1218359B1 (pt)
JP (1)	JP4776844B2 (pt)
KR (2)	KR100817373B1 (pt)
CN (1)	CN100413850C (pt)
AR (2)	AR025975A1 (pt)
AT (3)	ATE407125T1 (pt)
AU (1)	AU768780B2 (pt)
BR (1)	BR0014541A (pt)
CA (1)	CA2386515C (pt)
CO (1)	CO5251467A1 (pt)
CY (2)	CY1110172T1 (pt)
CZ (1)	CZ302340B6 (pt)
DE (3)	DE60042501D1 (pt)
DK (3)	DK1218359T3 (pt)
ES (3)	ES2222927T3 (pt)
GB (1)	GB9923748D0 (pt)
HK (1)	HK1052506B (pt)
HU (1)	HUP0203136A3 (pt)
IL (2)	IL148964A0 (pt)
MX (1)	MXPA02003515A (pt)
MY (1)	MY130907A (pt)
NO (1)	NO323776B1 (pt)
NZ (2)	NZ531127A (pt)
PE (1)	PE20010741A1 (pt)
PL (1)	PL201191B1 (pt)
PT (3)	PT1454901E (pt)
SI (3)	SI1218359T1 (pt)
TN (1)	TNSN00194A1 (pt)
TR (1)	TR200200936T2 (pt)
TW (1)	TWI225485B (pt)
WO (1)	WO2001025219A2 (pt)
ZA (1)	ZA200202589B (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2002537245A (ja) *	1999-02-18	2002-11-05	ノバルティスアクチエンゲゼルシャフト	５−ｈｔ３レセプターアンタゴニストの使用
USRE39921E1 (en)	1999-10-07	2007-11-13	Smithkline Beecham Corporation	Chemical compounds
GB9923748D0 (en) *	1999-10-07	1999-12-08	Glaxo Group Ltd	Chemical compounds
AUPQ514600A0 (en)	2000-01-18	2000-02-10	James Cook University	Brain injury treatment
GB0003232D0 (en) *	2000-02-11	2000-04-05	Smithkline Beecham Plc	Novel composition
GB0025354D0 (en)	2000-10-17	2000-11-29	Glaxo Group Ltd	Chemical compounds
GB0108594D0 (en) *	2001-04-05	2001-05-23	Glaxo Group Ltd	Chemical compounds
GB0108595D0 (en) *	2001-04-05	2001-05-23	Glaxo Group Ltd	Chemical compounds
US20030083345A1 (en) *	2001-07-10	2003-05-01	Torsten Hoffmann	Method of treatment and/or prevention of brain, spinal or nerve injury
GB0119797D0 (en) *	2001-08-14	2001-10-03	Glaxo Group Ltd	Chemical compounds
GB0124463D0 (en)	2001-10-11	2001-12-05	Smithkline Beecham Plc	Compounds
GB0203020D0 (en)	2002-02-08	2002-03-27	Glaxo Group Ltd	Chemical compounds
AU2003244455A1 (en)	2002-02-08	2003-09-02	Glaxo Group Limited	Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases
GB0203022D0 (en) *	2002-02-08	2002-03-27	Glaxo Group Ltd	Chemical compounds
DE10209145A1 (de) *	2002-03-01	2003-09-04	Bayer Cropscience Ag	Halogenbenzole
WO2003101459A1 (en) *	2002-05-29	2003-12-11	The Regents Of The University Of California	Antagonizing nk1 receptors inhibits consumption of substances of abuse
JP4079727B2 (ja) *	2002-09-06	2008-04-23	セントラル硝子株式会社	光学活性１−（フルオロ、トリフルオロメチルまたはトリフルオロメトキシ置換フェニル）アルキルアミンｎ−モノアルキル誘導体とその製造方法
JP2006516581A (ja) *	2003-01-27	2006-07-06	グラクソ　グループ　リミテッド	機能性消化不良を治療するための化学化合物の使用
GB0308968D0 (en) *	2003-04-17	2003-05-28	Glaxo Group Ltd	Medicaments
CA2528652A1 (en) *	2003-06-19	2004-12-23	Pfizer Products Inc.	Nk1 antagonist
US20050113365A1 (en) *	2003-11-10	2005-05-26	Sir Isaac Newton Enterprises Llc	Method and medicine for treating gastrointestinal disorder including irritable bowel syndrome
US20060148782A1 (en) *	2003-11-10	2006-07-06	Lundeen James E	Method and medicine for treating a mammal presenting urinary incontinence, urinary urgency, or both
US20060148783A1 (en) *	2003-11-10	2006-07-06	Lundeen James E	Method and medicine for treating gastrointestinal disorder including fecal incontinence
US20060148781A1 (en) *	2003-11-10	2006-07-06	Lundeen James E	Method and medicine for treating gastrointestinal disorder in a non-human mammal
US20070142367A1 (en) *	2003-11-10	2007-06-21	Lundeen James E	Method and medicine for treating gastrointestinal disorder including fecal incontinence
WO2005051912A1 (ja) *	2003-11-28	2005-06-09	Tanabe Seiyaku Co., Ltd.	ピペリジン化合物およびその製法
EP1705176A4 (en) *	2004-01-14	2009-06-03	Takeda Pharmaceutical	CARBOXYLAMIDE DERIVATIVE AND ITS USE
DE602006015215D1 (de) *	2005-10-10	2010-08-12	Glaxo Group Ltd	Prolinamidderivate als natriumkanalmodulatoren
TW200730494A (en) *	2005-10-10	2007-08-16	Glaxo Group Ltd	Novel compounds
US20100009983A1 (en) *	2006-05-09	2010-01-14	Braincells, Inc.	5 ht receptor mediated neurogenesis
JP4904945B2 (ja)	2006-06-30	2012-03-28	セントラル硝子株式会社	光学活性１−（フルオロ、トリフルオロメチルまたはトリフルオロメトキシ置換フェニル）アルキルアミンｎ−モノアルキル誘導体の製造方法
GB0621229D0 (en) *	2006-10-20	2006-12-06	Glaxo Group Ltd	Novel use
JP2010516731A (ja)	2007-01-24	2010-05-20	グラクソグループリミテッド	２−メトキシ−５−（５−トリフルオロメチル−テトラゾール−１−イル）−ベンジル］−（２ｓ−フェニル−ピペリジン−３ｓ−イル）−アミンを含む医薬組成物
JP5510040B2 (ja) *	2010-04-28	2014-06-04	セントラル硝子株式会社	光学活性（ｒ）−１−（４−フルオロフェニル）エチルアミンを得る光学分割
WO2012175434A1 (en)	2011-06-20	2012-12-27	Glaxo Group Limited	Pharmaceutical formulations comprising vestipitant
ES2672099T3 (es)	2011-07-04	2018-06-12	Irbm - Science Park S.P.A.	Antagonistas del receptor NK-1 para el tratamiento de la neovascularización corneal
ES2568909T3 (es)	2012-02-22	2016-05-05	Leo Pharma A/S	Novedosos compuestos antagonistas del receptor de la neuroquinina 1
WO2015024203A1 (en)	2013-08-20	2015-02-26	Leo Pharma A/S	Novel neurokinin 1 receptor antagonist compounds ii
ES2912881T3 (es)	2014-12-23	2022-05-30	Convergence Pharmaceuticals	Procedimiento para preparar derivados de alfa-carboxamida pirrolidina
EP3388423B1 (en) *	2015-12-07	2020-05-27	Kissei Pharmaceutical Co., Ltd.	Nk1 receptor antagonist
IL312486B2 (en)	2017-04-10	2025-05-01	Chase Therapeutics Corp	NK1 antagonist combination and method for treating synucleinopathies
KR20200026920A (ko)	2017-06-30	2020-03-11	체이스 테라퓨틱스 코포레이션	우울증을 치료하기 위한 nk-1 길항제 조성물 및 우울증 치료에 사용하는 방법
CA3076823A1 (en)	2017-10-05	2019-04-11	Biogen Inc.	Process for preparing alpha-carboxamide pyrrolidine derivatives

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1334812A (en) *	1919-07-23	1920-03-23	Theodore T Snow	Post
US4110327A (en)	1974-05-09	1978-08-29	Toyama Chemical Co., Ltd.	2,3 Diketo-piperazinocarbonylamino alkanoic acids and derivatives
US4379152A (en)	1974-05-09	1983-04-05	Toyama Chemical Co., Ltd.	Cephalosporins
US4219554A (en)	1974-05-09	1980-08-26	Toyama Chemical Company, Limited	Novel penicillins and cephalosporins and process for producing same
US4087424A (en)	1974-05-09	1978-05-02	Toyama Chemical Co., Ltd.	Novel penicillins and cephalosporins and process for producing the same
US4112090A (en)	1974-05-09	1978-09-05	Toyama Chemical Co., Ltd.	Novel penicillins and cephalosporins and process for producing the same
US4410522A (en)	1974-05-09	1983-10-18	Toyama Chemical Co., Ltd.	Cephalosporins
US4327097A (en)	1974-05-09	1982-04-27	Toyama Chemical Co., Ltd.	Novel penicillins
IL47168A (en)	1974-05-09	1979-07-25	Toyama Chemical Co Ltd	Mono or dioxo piperazino(thio)carbonylamino derivatives ofpenicillins and cephalosporins and process for producing the same
NO154582C (no)	1978-10-20	1986-11-05	Ferrosan Ab	Analogifremgangsmaate for fremstilling av terapeutisk aktive difenyl-dibutylpiperazinkarboksamider.
JPS57118587A (en)	1981-11-26	1982-07-23	Toyama Chem Co Ltd	Novel penicillin
US5028610A (en)	1987-03-18	1991-07-02	Sankyo Company Limited	N-benzhydryl-substituted heterocyclic derivatives, their preparation and their use
GB8709666D0 (en)	1987-04-23	1987-05-28	Beecham Group Plc	Compounds
GB8713061D0 (en)	1987-06-04	1987-07-08	Beecham Group Plc	Compounds
US5109014A (en)	1990-12-10	1992-04-28	Jacobson Richard M	N-aryl-3-aryl-4-substituted-2,3,4,5-tetrahydro-1H-pyrazole-1-carboxamides
SE9100860D0 (sv)	1991-03-22	1991-03-22	Kabi Pharmacia Ab	New use
EP1082959A1 (en)	1991-09-20	2001-03-14	Glaxo Group Limited	NK1 Antagonists for the treatment of depression
EP0545478A1 (en)	1991-12-03	1993-06-09	MERCK SHARP & DOHME LTD.	Heterocyclic compounds as tachykinin antagonists
US5563127A (en)	1993-03-24	1996-10-08	The Dupont Merck Pharmaceutical Company	Boronic acid and ester inhibitors of thrombin
US5348955A (en)	1993-06-22	1994-09-20	Merck & Co., Inc.	N,N-diacylpiperazines
IL111730A (en)	1993-11-29	1998-12-06	Fujisawa Pharmaceutical Co	Piperazine derivatives processes for the preparation thereof and pharmaceutical compositions containing the same
IL112778A0 (en)	1994-03-04	1995-05-26	Merck & Co Inc	Substituted heterocycles, their preparation and pharmaceutical compositions containing them
US5464788A (en)	1994-03-24	1995-11-07	Merck & Co., Inc.	Tocolytic oxytocin receptor antagonists
DE4425146A1 (de)	1994-07-15	1996-01-18	Basf Ag	Verwendung heterocyclischer Verbindungen
AU3085895A (en)	1994-07-26	1996-02-22	Sankyo Company Limited	N-phenylated amide and urea derivatives
US5696123A (en)	1994-09-17	1997-12-09	Boehringer Ingelheim Kg	Neurokinin antagonists
DE19520499C2 (de)	1994-09-17	2003-06-18	Boehringer Ingelheim Kg	Neurokinin-Antagonisten, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende pharmazeutische Zusammensetzungen sowie ihre Verwendung
US5998444A (en)	1995-10-24	1999-12-07	Zeneca Ltd.	Piperidinyl compounds as NK1 or NK2 antagonists
EP0709375B1 (en)	1994-10-25	2005-05-18	AstraZeneca AB	Therapeutic heterocycles
US5629322A (en)	1994-11-15	1997-05-13	Merck & Co., Inc.	Cyclic amidine analogs as inhibitors of nitric oxide synthase
US5576317A (en)	1994-12-09	1996-11-19	Pfizer Inc.	NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
US5700801A (en)	1994-12-23	1997-12-23	Karl Thomae, Gmbh	Piperazine derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them
CA2207618A1 (en)	1994-12-23	1996-07-04	Helmut Pieper	Piperazine derivatives, medicaments comprising these compounds, their use and processes for their preparation
NZ321575A (en)	1995-10-30	1999-05-28	Janssen Pharmaceutica Nv	1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives
DE19608665A1 (de)	1996-03-06	1997-09-11	Boehringer Ingelheim Kg	Neue Arylglycinamidderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US6057323A (en)	1996-03-08	2000-05-02	Adolor Corporation	Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
JP2000507579A (ja)	1996-04-03	2000-06-20	メルクエンドカンパニーインコーポレーテッド	ファルネシル―タンパク質トランスフェラーゼ阻害剤
US5859012A (en)	1996-04-03	1999-01-12	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
CA2249604A1 (en)	1996-04-03	1997-10-09	Theresa M. Williams	Inhibitors of farnesyl-protein transferase
AU706495B2 (en)	1996-04-03	1999-06-17	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
AU3359697A (en)	1996-07-08	1998-02-02	Yamanouchi Pharmaceutical Co., Ltd.	Bone resorption inhibitors
JP2000514455A (ja) *	1996-07-17	2000-10-31	メルクエンドカンパニーインコーポレーテッド	タキキニンアンタゴニストによるサーカディアンリズムの改変
US6117855A (en)	1996-10-07	2000-09-12	Merck Sharp & Dohme Ltd.	Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
US5929077A (en)	1996-11-08	1999-07-27	Leftheris; Katerina	Thioproline-containing inhibitors of farnesyl protein transferase
US6114315A (en)	1996-12-02	2000-09-05	Merck Sharp & Dohme Ltd.	Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety
US5977104A (en)	1996-12-02	1999-11-02	Merck Sharp & Dohme Ltd.	Use of NK-1 receptor antagonists for treating bipolar disorders
AU731672B2 (en)	1996-12-02	2001-04-05	Merck Sharp & Dohme Limited	Use of NK-1 receptor antagonists for treating bipolar disorders
AUPO735997A0 (en)	1997-06-17	1997-07-10	Fujisawa Pharmaceutical Co., Ltd.	Piperazine derivatives
CA2301770A1 (en)	1997-08-27	1999-03-04	Merck & Co., Inc.	Inhibitors of prenyl-protein transferase
WO1999026921A1 (en)	1997-11-24	1999-06-03	Merck & Co., Inc.	SUBSTITUTED β-ALANINE DERIVATIVES AS CELL ADHESION INHIBITORS
WO2000035915A1 (en) *	1998-12-14	2000-06-22	Fujisawa Pharmaceutical Co., Ltd.	Piperazine derivatives
GB9923748D0 (en) *	1999-10-07	1999-12-08	Glaxo Group Ltd	Chemical compounds
AU7788500A (en) *	1999-10-25	2001-05-08	Janssen Pharmaceutica N.V.	Use of substance p antagonists for influencing the circadian timing system
GB0025354D0 (en)	2000-10-17	2000-11-29	Glaxo Group Ltd	Chemical compounds
US20030022891A1 (en)	2000-12-01	2003-01-30	Anandan Palani	MCH antagonists and their use in the treatment of obesity
MY141736A (en)	2002-10-08	2010-06-15	Elanco Animal Health Ireland	Substituted 1,4-di-piperidin-4-yi-piperazine derivatives and their use as neurokinin antagonists

1999
- 1999-10-07 GB GBGB9923748.9A patent/GB9923748D0/en not_active Ceased
2000
- 2000-10-05 ES ES00969414T patent/ES2222927T3/es not_active Expired - Lifetime
- 2000-10-05 CO CO00075822A patent/CO5251467A1/es active IP Right Grant
- 2000-10-05 PT PT04076650T patent/PT1454901E/pt unknown
- 2000-10-05 CZ CZ20021166A patent/CZ302340B6/cs not_active IP Right Cessation
- 2000-10-05 PT PT00969414T patent/PT1218359E/pt unknown
- 2000-10-05 MX MXPA02003515A patent/MXPA02003515A/es active IP Right Grant
- 2000-10-05 CA CA2386515A patent/CA2386515C/en not_active Expired - Lifetime
- 2000-10-05 KR KR1020027004438A patent/KR100817373B1/ko not_active Expired - Fee Related
- 2000-10-05 SI SI200030492T patent/SI1218359T1/xx unknown
- 2000-10-05 CN CNB008158606A patent/CN100413850C/zh not_active Expired - Fee Related
- 2000-10-05 HU HU0203136A patent/HUP0203136A3/hu unknown
- 2000-10-05 DK DK00969414T patent/DK1218359T3/da active
- 2000-10-05 IL IL14896400A patent/IL148964A0/xx active IP Right Grant
- 2000-10-05 PL PL356261A patent/PL201191B1/pl unknown
- 2000-10-05 BR BR0014541-6A patent/BR0014541A/pt not_active Application Discontinuation
- 2000-10-05 KR KR1020077026231A patent/KR100857671B1/ko not_active Expired - Fee Related
- 2000-10-05 DE DE60042501T patent/DE60042501D1/de not_active Expired - Lifetime
- 2000-10-05 AU AU79139/00A patent/AU768780B2/en not_active Ceased
- 2000-10-05 NZ NZ531127A patent/NZ531127A/en not_active IP Right Cessation
- 2000-10-05 EP EP00969414A patent/EP1218359B1/en not_active Expired - Lifetime
- 2000-10-05 HK HK03104740.2A patent/HK1052506B/zh not_active IP Right Cessation
- 2000-10-05 AT AT04076650T patent/ATE407125T1/de active
- 2000-10-05 DE DE60040176T patent/DE60040176D1/de not_active Expired - Lifetime
- 2000-10-05 ES ES04076632T patent/ES2329130T3/es not_active Expired - Lifetime
- 2000-10-05 WO PCT/EP2000/009722 patent/WO2001025219A2/en not_active Ceased
- 2000-10-05 SI SI200031037T patent/SI1460066T1/sl unknown
- 2000-10-05 JP JP2001528165A patent/JP4776844B2/ja not_active Expired - Fee Related
- 2000-10-05 TR TR2002/00936T patent/TR200200936T2/xx unknown
- 2000-10-05 AT AT00969414T patent/ATE270664T1/de active
- 2000-10-05 MY MYPI20004668A patent/MY130907A/en unknown
- 2000-10-05 US US10/089,964 patent/US6951861B1/en not_active Expired - Lifetime
- 2000-10-05 EP EP04076632A patent/EP1460066B1/en not_active Expired - Lifetime
- 2000-10-05 DE DE60012031T patent/DE60012031T2/de not_active Expired - Lifetime
- 2000-10-05 EP EP04076650A patent/EP1454901B1/en not_active Expired - Lifetime
- 2000-10-05 NZ NZ518144A patent/NZ518144A/xx not_active IP Right Cessation
- 2000-10-05 DK DK04076632T patent/DK1460066T3/da active
- 2000-10-05 AT AT04076632T patent/ATE435215T1/de active
- 2000-10-05 PT PT04076632T patent/PT1460066E/pt unknown
- 2000-10-05 DK DK04076650T patent/DK1454901T3/da active
- 2000-10-05 SI SI200031010T patent/SI1454901T1/sl unknown
- 2000-10-05 ES ES04076650T patent/ES2312917T3/es not_active Expired - Lifetime
- 2000-10-06 PE PE2000001068A patent/PE20010741A1/es not_active Application Discontinuation
- 2000-10-06 TN TNTNSN00194A patent/TNSN00194A1/en unknown
- 2000-10-06 AR ARP000105284A patent/AR025975A1/es not_active Application Discontinuation
- 2000-10-07 TW TW089121014A patent/TWI225485B/zh not_active IP Right Cessation
2002
- 2002-04-01 IL IL148964A patent/IL148964A/en not_active IP Right Cessation
- 2002-04-03 ZA ZA200202589A patent/ZA200202589B/en unknown
- 2002-04-05 NO NO20021637A patent/NO323776B1/no not_active IP Right Cessation
- 2002-07-03 US US10/190,170 patent/US6642240B2/en not_active Ceased
2003
- 2003-08-08 US US10/637,825 patent/US7071196B2/en not_active Expired - Fee Related
2004
- 2004-05-04 US US10/838,838 patent/US20040209893A1/en not_active Abandoned
2006
- 2006-01-18 US US11/334,267 patent/US7345041B2/en not_active Expired - Fee Related
2007
- 2007-12-13 US US11/955,847 patent/US7625904B2/en not_active Expired - Fee Related
2008
- 2008-11-27 CY CY20081101376T patent/CY1110172T1/el unknown
2009
- 2009-09-18 CY CY20091100969T patent/CY1110104T1/el unknown
2010
- 2010-07-15 AR ARP100102567A patent/AR077414A2/es unknown

Also Published As

Publication number	Publication date
AU768780B2 (en)	2004-01-08
NZ518144A (en)	2004-04-30
US20030028021A1 (en)	2003-02-06
EP1454901B1 (en)	2008-09-03
ZA200202589B (en)	2003-08-27
US6951861B1 (en)	2005-10-04
NO20021637D0 (no)	2002-04-05
CA2386515C (en)	2011-06-07
KR100817373B1 (ko)	2008-03-27
US6642240B2 (en)	2003-11-04
ES2312917T3 (es)	2009-03-01
KR100857671B1 (ko)	2008-09-08
NO20021637L (no)	2002-06-06
TR200200936T2 (tr)	2002-07-22
DE60012031D1 (de)	2004-08-12
US20040209893A1 (en)	2004-10-21
EP1454901A1 (en)	2004-09-08
PL356261A1 (en)	2004-06-28
CY1110104T1 (el)	2015-01-14
GB9923748D0 (en)	1999-12-08
DK1460066T3 (da)	2009-11-02
WO2001025219A2 (en)	2001-04-12
AU7913900A (en)	2001-05-10
KR20020038800A (ko)	2002-05-23
KR20070112308A (ko)	2007-11-22
SI1460066T1 (sl)	2009-12-31
CZ302340B6 (cs)	2011-03-23
US7345041B2 (en)	2008-03-18
DK1218359T3 (da)	2004-10-18
US20060122192A1 (en)	2006-06-08
AR025975A1 (es)	2002-12-26
HK1052506B (zh)	2008-12-19
SI1218359T1 (en)	2005-02-28
JP4776844B2 (ja)	2011-09-21
DE60040176D1 (de)	2008-10-16
ATE435215T1 (de)	2009-07-15
ES2329130T3 (es)	2009-11-23
HK1065798A1 (en)	2005-03-04
US20080249108A1 (en)	2008-10-09
PL201191B1 (pl)	2009-03-31
TNSN00194A1 (en)	2005-11-10
BR0014541A (pt)	2002-09-17
EP1460066B1 (en)	2009-07-01
MXPA02003515A (es)	2002-09-02
US7071196B2 (en)	2006-07-04
PT1218359E (pt)	2004-10-29
IL148964A (en)	2007-02-11
EP1218359B1 (en)	2004-07-07
DK1454901T3 (da)	2009-01-12
HK1066537A1 (en)	2005-03-24
HUP0203136A2 (hu)	2003-02-28
IL148964A0 (en)	2002-11-10
EP1218359A2 (en)	2002-07-03
ES2222927T3 (es)	2005-02-16
NZ531127A (en)	2005-11-25
US20040048862A1 (en)	2004-03-11
DE60042501D1 (de)	2009-08-13
CO5251467A1 (es)	2003-02-28
CA2386515A1 (en)	2001-04-12
CZ20021166A3 (cs)	2002-11-13
CN1391564A (zh)	2003-01-15
PT1454901E (pt)	2008-12-12
SI1454901T1 (sl)	2009-02-28
ATE407125T1 (de)	2008-09-15
TWI225485B (en)	2004-12-21
CY1110172T1 (el)	2015-01-14
EP1460066A1 (en)	2004-09-22
PE20010741A1 (es)	2001-07-18
AR077414A2 (es)	2011-08-24
MY130907A (en)	2007-07-31
HUP0203136A3 (en)	2003-03-28
NO323776B1 (no)	2007-07-02
ATE270664T1 (de)	2004-07-15
CN100413850C (zh)	2008-08-27
JP2003511377A (ja)	2003-03-25
US7625904B2 (en)	2009-12-01
WO2001025219A3 (en)	2001-12-13
HK1052506A1 (zh)	2003-09-19
DE60012031T2 (de)	2005-07-07

Publication	Publication Date	Title
PT1460066E (pt)	2009-09-10	Compostos de piperazina úteis como inibidores de taquicininas
HUP0202713A3 (en)	2005-02-28	Pteridinones as kinase inhibitors
GB9912961D0 (en)	1999-08-04	Metalloprotease inhibitors
IL153661A0 (en)	2003-07-06	Piperidine compounds for use as ccr-3 inhibitors
GB9900416D0 (en)	1999-02-24	Inhibitors
IL145764A0 (en)	2002-07-25	Pyrazolobenzodiazepines as cdk2 inhibitors
IL156064A0 (en)	2003-12-23	Vla-4 inhibitors
SI1686119T1 (sl)	2009-12-31	Derivati pirimidin-5-ona kot inhibitorji ldl-pla2
IL146288A0 (en)	2002-07-25	Vla-4 inhibitor compounds
IL148818A0 (en)	2002-09-12	Piperazine derivatives as 5-ht1b
AU2001248748A1 (en)	2001-10-30	Substituted piperazine compounds
IL145085A0 (en)	2002-06-30	Dihetero-substituted metalloprotease inhibitors
IL150114A0 (en)	2002-12-01	Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
PL362564A1 (en)	2004-11-02	Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
IL145955A0 (en)	2002-07-25	New pharmaceutical combinations for nos inhibitors
IL150357A0 (en)	2002-12-01	Substituted piperazine derivatives as mtp inhibitors
IL152979A0 (en)	2003-06-24	Heterocyclic compounds
AU2001238590A1 (en)	2001-09-03	Substituted piperazine compounds
AU3862301A (en)	2001-09-03	Substituted piperazine compounds
AP2002002413A0 (en)	2002-03-31	Heterocyclic compounds inhibiting angiogenesi
EP1153022A4 (en)	2002-03-27	PROTEASE INHIBITORS
IL132315A0 (en)	2001-03-19	Compositions comprising oxophosphonate-based metalloproteinase inhibitors
SI1109560T1 (en)	2004-02-29	Compounds useful as aicarft inhibitors
GB9922446D0 (en)	1999-11-24	Amine compounds
GB9917294D0 (en)	1999-09-22	Inhibitors